As a result, XPO1 inhibitors block the nuclear export activity of particular proteins that XPO1 mediates, which reinstates the apoptotic pathway and increases the susceptibility of tumor cells to chemotherapy medications such as doxorubicin, tyrosine kinase inhibitor imatinib, etc. This specific inhibitor has emerged as a new focal point in cancer therapy. Here, XPO1 is linked to neoplasm.